Issue 3/2007
Content (12 Articles)
Use of progression-free survival as a valid endpoint in phase II cancer clinical trials
Maurie Markman
Combined-modality therapy for esophageal and gastroesophageal junction cancers
Harry H. Yoon, Michael K. Gibson
Shifting from clinical to biologic indicators of prognosis after resection of hepatic colorectal metastases
Timothy M. Pawlik, Michael A. Choti
Rationale for, and approach to, studying modifiers of risk in persons with a genetic predisposition to colorectal cancer
Mark A. Jenkins, Melissa C. Southey, Graham G. Giles, John L. Hopper
Clinical trials in metastatic hormone-refractory prostate cancer: Improving docetaxel therapy by targeting bone-related growth factors
Daniel P. Petrylak